| Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis … C Thiede, C Steudel, B Mohr, M Schaich, U Schäkel, U Platzbecker, ... Blood, The Journal of the American Society of Hematology 99 (12), 4326-4335, 2002 | 2145 | 2002 |
| The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms JD Khoury, E Solary, O Abla, Y Akkari, R Alaggio, JF Apperley, R Bejar, ... leukemia 36 (7), 1703-1719, 2022 | 1956 | 2022 |
| Retinoic acid and arsenic trioxide for acute promyelocytic leukemia F Lo-Coco, G Avvisati, M Vignetti, C Thiede, SM Orlando, S Iacobelli, ... New England Journal of Medicine 369 (2), 111-121, 2013 | 1684* | 2013 |
| Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet L Malcovati, E Hellström-Lindberg, D Bowen, L Adès, J Cermak, ... Blood, The Journal of the American Society of Hematology 122 (17), 2943-2964, 2013 | 801 | 2013 |
| International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium AC Harris, R Young, S Devine, WJ Hogan, F Ayuk, U Bunworasate, ... Biology of Blood and Marrow Transplantation 22 (1), 4-10, 2016 | 667 | 2016 |
| Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final … M Lübbert, S Suciu, L Baila, BH Rüter, U Platzbecker, A Giagounidis, ... Journal of clinical oncology 29 (15), 1987-1996, 2011 | 648 | 2011 |
| A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q P Fenaux, A Giagounidis, D Selleslag, O Beyne-Rauzy, G Mufti, ... Blood, The Journal of the American Society of Hematology 118 (14), 3765-3776, 2011 | 566 | 2011 |
| Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet MA Sanz, P Fenaux, MS Tallman, EH Estey, B Löwenberg, T Naoe, ... Blood, The Journal of the American Society of Hematology 133 (15), 1630-1643, 2019 | 544 | 2019 |
| Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes E Bernard, Y Nannya, RP Hasserjian, SM Devlin, H Tuechler, ... Nature medicine 26 (10), 1549-1556, 2020 | 481 | 2020 |
| Luspatercept in patients with lower-risk myelodysplastic syndromes P Fenaux, U Platzbecker, GJ Mufti, G Garcia-Manero, R Buckstein, ... New England Journal of Medicine 382 (2), 140-151, 2020 | 473 | 2020 |
| Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial U Platzbecker, M Wermke, J Radke, U Oelschlaegel, F Seltmann, A Kiani, ... Leukemia 26 (3), 381-389, 2012 | 446 | 2012 |
| Molecular international prognostic scoring system for myelodysplastic syndromes E Bernard, H Tuechler, PL Greenberg, RP Hasserjian, JE Arango Ossa, ... NEJM evidence 1 (7), EVIDoa2200008, 2022 | 436 | 2022 |
| Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit H Medyouf, M Mossner, JC Jann, F Nolte, S Raffel, C Herrmann, A Lier, ... Cell stem cell 14 (6), 824-837, 2014 | 430 | 2014 |
| Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non–high-risk acute promyelocytic leukemia: final results of the … U Platzbecker, G Avvisati, L Cicconi, C Thiede, F Paoloni, M Vignetti, ... Journal of Clinical Oncology 35 (6), 605-612, 2017 | 399 | 2017 |
| P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate T Illmer, M Schaich, U Platzbecker, J Freiberg-Richter, U Oelschlägel, ... Leukemia 18 (3), 401-408, 2004 | 395 | 2004 |
| Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium M Von Bonin, F Stölzel, A Goedecke, K Richter, N Wuschek, K Hölig, ... Bone marrow transplantation 43 (3), 245-251, 2009 | 390 | 2009 |
| Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel T De Witte, D Bowen, M Robin, L Malcovati, D Niederwieser, ... Blood, The Journal of the American Society of Hematology 129 (13), 1753-1762, 2017 | 378 | 2017 |
| Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia … J Donadieu, T Leblanc, BB Meunier, M Barkaoui, O Fenneteau, ... haematologica 90 (1), 45-53, 2005 | 348 | 2005 |
| Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term … U Platzbecker, U Germing, KS Götze, P Kiewe, K Mayer, J Chromik, ... The Lancet Oncology 18 (10), 1338-1347, 2017 | 322 | 2017 |
| Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2 … U Platzbecker, JM Middeke, K Sockel, R Herbst, D Wolf, CD Baldus, ... The Lancet Oncology 19 (12), 1668-1679, 2018 | 296 | 2018 |
